# SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

> **NCT07374549** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** SYS6002
- **DRUG:** enfortumab vedotin

## Key facts

- **NCT ID:** NCT07374549
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-20
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07374549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07374549, "SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07374549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*